| OA | LAI | p-value | |
| N | 51 | 79 | |
| Male | 31 (61%) | 50 (64%) | 0.70 |
| Age, mean (SD) | 46.5 (13) | 47.4 (13) | 0.69 |
| Duration of Illness, mean (SD) | 8.9 (3.1) | 8.5 (3.1) | 0.55 |
| Antipsychotics (more than 1) | 21 (41%) | 74 (94%) | <0.001 |
| Oral antipsychotics (more than one) | 21 (41%) | 40 (51%) | 0.29 |
| RA (D2) | 8 (16%) | 40 (51%) | <0.001 |
| RA (D2, 5-HT2) | 24 (47%) | 31 (39%) | 0.38 |
| RA (D2, 5-HT2, NE alpha-2) | 24 (47%) | 45 (57%) | 0.27 |
| RpA (D2, 5-HT1A) and RA (5-HT2A) | 7 (14%) | 9 (11%) | 0.69 |
| RA (D2, 5-HT2) and reuptake inhibitor (NET) | 6 (12%) | 23 (29%) | 0.020 |
| Mood stabilizers, mean (SD) | 0.3 (0.5) | 0.2 (0.5) | 0.60 |
| Antidepressants, mean (SD) | 0.6 (0.8) | 0.5 (0.8) | 0.70 |
| Anxiolytics, mean (SD) | 0.7 (0.8) | 0.8 (0.9) | 0.60 |
| Hypnotics, mean (SD) | 0.2 (0.5) | 0.1 (0.4) | 0.62 |